Foreign Filer Report • Jan 17, 2024
Foreign Filer Report
Open in ViewerOpens in native device viewer
Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug false
| ����� ��"� | 2 380 |
| EVOGENE LTD | |
| Corporation no: 512838723 | 13041 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 17/01/2024 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2024-02-007566 | Time of broadcast: 13:33 13:33 |
The corporation scheduled the publication of the report to 17/01/2024 14:00Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report onBiomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
1705489997_a2430788_organized_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: -1 | Date of revision of form structure: 31/12/2023 |
| Address: Gad Feinstein St 13, P.O.B 2100 , Rehovot 76121 , Tel: 08-9311900 , Fax: 08-9466724 | |
| E-mail address: [email protected] Company site: www.evogene.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Kofman Guy Position of Signatory in the reporting corporation: Lawyer/ Legal Counsel Name of Employer Company: | |
| Address: Gad Feinstein St. 13 , Rehovot 7638517 Telephone: 08-9311962 Facsimile: 08-9466724 E-mail: [email protected] 1 | |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.